|
| Number of responders to the question | % of correct answers | CI 95% |
|
BRCA1/2 | | | |
Genetic tests for BRCA1/BRCA2 mutations are able to identify patients at high risk to develop breast cancer (agree, uncertain, disagree) | 357 | 93.3 | 90.2–95.6 |
The percentage of breast cancer cases associated with mutations in BRCA1/BRCA2 is 1–10%, 15–35%, >35% | 354 | 42.9 | 37.7–48.3 |
The absolute risk of developing breast cancer in presence of BRCA1/BRCA2 mutations is <10%, 40–80%, 100% | 356 | 80.3 | 75.8–84.3 |
Women with breast cancer and strong family history should perform BRCA1/BRCA2 testing (agree, uncertain, disagree) | 356 | 78.7 | 74.0–82.8 |
Scientific evidence recommend for BRCA1/BRCA2 positive women clinical and instrumental surveillance starting from the age of 25 (agree, uncertain, disagree) | 358 | 84.4 | 80.2–88.0 |
APC | | | |
Genetic tests for APC mutations are able to identify patients who will develop colorectal carcinoma (agree, uncertain, disagree) | 355 | 77.7 | 73.1–82.0 |
The percentage of colon cancer cases associated with APC mutations is <5%, 10–25%, >40% | 352 | 31.8 | 27.0–37.0 |
The absolute risk of developing colorectal cancer in presence of APC mutations is <10%, 40–80%, 100% | 351 | 27.9 | 23.3–32.9 |
APC testing is recommended for 10–12 years old children with a first degree relative with known APC mutation (agree, uncertain, disagree) | 357 | 57.4 | 52.1–62.6 |
Scientific evidence recommend for APC positive individuals periodic colonoscopy starting from the age of 10–15 (agree, uncertain, disagree) | 356 | 55.9 | 50.6–61.1 |
|